SLC5A2 and Myocardial fibrosis: These include the effect of empagliflozin on infarct size, intramyocardial haemorrhage and remote zone myocardial fibrosis along with circulating biomarkers of pro‐fibrotic processes, the relationship between SGLT2 inhibitors' effects on erythropoiesis, iron metabolism and ventricular remodelling, and the effect on biomarkers of inflammation (e.g., interleukin‐6, high sensitivity C‐reactive protein, and tissue necrosis factor‐α).47, 48, 49